MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 534848 | Name: Tiuxetan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tiuxetan is a bioactive chemical.

Chemical Structure

Tiuxetan
CAS#108414-96-6

Theoretical Analysis

MedKoo Cat#: 534848

Name: Tiuxetan

CAS#: 108414-96-6

Chemical Formula: C23H30N4O10S

Exact Mass: 554.1683

Molecular Weight: 554.57

Elemental Analysis: C, 49.81; H, 5.45; N, 10.10; O, 28.85; S, 5.78

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Tiuxetan
IUPAC/Chemical Name
Glycine, N-(2-(bis(carboxymethyl)amino)-3-(4-isothiocyanatophenyl)propyl)-N-(2-(bis(carboxymethyl)amino)propyl)-
InChi Key
FZDFGHZZPBUTGP-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H30N4O10S/c1-15(26(10-20(30)31)11-21(32)33)7-25(9-19(28)29)8-18(27(12-22(34)35)13-23(36)37)6-16-2-4-17(5-3-16)24-14-38/h2-5,15,18H,6-13H2,1H3,(H,28,29)(H,30,31)(H,32,33)(H,34,35)(H,36,37)
SMILES Code
O=C(O)CN(CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1)CC(N(CC(O)=O)CC(O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 554.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mukherjee S, Ayanambakkam A, Ibrahimi S, Schmidt S, Charkrabarty JH, Khawandanah M. Ibritumomab tiuxetan (Zevalin) and elevated serum human anti- murine antibody (HAMA). Hematol Oncol Stem Cell Ther. 2018 Sep;11(3):187-188. doi: 10.1016/j.hemonc.2017.12.004. Epub 2018 Feb 1. PMID: 29406240. 2: Rizzieri D. Zevalin(®) (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016 Sep;105:5-17. doi: 10.1016/j.critrevonc.2016.07.008. Epub 2016 Jul 16. PMID: 27497027. 3: Mondello P, Cuzzocrea S, Navarra M, Mian M. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityr. Oncotarget. 2016 Feb 16;7(7):7597-609. doi: 10.18632/oncotarget.6531. PMID: 26657116; PMCID: PMC4884941. 4: Johnston PB, Bondly C, Micallef IN. Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9. doi: 10.1586/14737140.6.6.861. PMID: 16761929. 5: Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group. Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study. Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10. PMID: 31290569. 6: The MICAD Research Team. 111In-Ibritumomab tiuxetan. 2005 Nov 22 [updated 2007 Sep 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641438. 7: Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A. 90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience. Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3. PMID: 29993147. 8: Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs Today (Barc). 2004 Feb;40(2):111-9. doi: 10.1358/dot.2004.40.2.799423. PMID: 15045033. 9: Baus A, Keilani C, Bich CS, Entine F, Brachet M, Duhamel P, Amabile JC, Malfuson JV, Bey E. Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of Yttrium-90-ibritumomab Tiuxetan: A case report and literature review. Ann Chir Plast Esthet. 2018 Apr;63(2):175-181. doi: 10.1016/j.anplas.2017.11.007. Epub 2017 Dec 28. PMID: 29290464. 10: Hagenbeek A. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma. 2003;44 Suppl 4:S37-47. doi: 10.1080/10428190310001616944. PMID: 15154741. 11: Cheung MC, Haynes AE, Stevens A, Meyer RM, Imrie K; Members of the Hematology Disease Site Group of the Cancer Care Ontario Program in Evidence- Based Care. Yttrium 90 ibritumomab tiuxetan in lymphoma. Leuk Lymphoma. 2006 Jun;47(6):967-77. doi: 10.1080/10428190600572582. Erratum in: Leuk Lymphoma. 2006 Aug;47(8):1719-20. PMID: 16840185. 12: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Yttrium 90 Ibritumomab Tiuxetan. 2018 Dec 3. PMID: 29999770. 13: Iino M, Sakamoto Y, Sato T. Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience. Hematology. 2019 Dec;24(1):623-630. doi: 10.1080/16078454.2019.1664094. PMID: 31496425. 14: Gregory SA. Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003 Dec;30(6 Suppl 17):17-22. doi: 10.1053/j.seminoncol.2003.10.004. PMID: 14710399. 15: Jurczak W, Gruszka AM, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, Giza A, Krawczyk K, Jakobczyk M, Hubalewska-Dydejczyk A, Szymczyk M, Wróbel T, Knopińska-Posłuszny W, Kisiel E, Skotnicki A, Zinzani PL. Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. Leuk Lymphoma. 2019 Nov;60(11):2689-2696. doi: 10.1080/10428194.2019.1602261. Epub 2019 Apr 9. PMID: 30961415. 16: Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-76. doi: 10.2967/jnumed.107.043489. Epub 2007 Oct 17. PMID: 17942813. 17: Morschhauser F, Dekyndt B, Baillet C, Barthélémy C, Malek E, Fulcrand J, Bigot P, Huglo D, Décaudin B, Simon N, Odou P. A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry. Sci Rep. 2018 Oct 5;8(1):14860. doi: 10.1038/s41598-018-33160-0. PMID: 30291297; PMCID: PMC6173718. 18: Micallef IN. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. Clin Lymphoma. 2004 Oct;5 Suppl 1:S27-32. doi: 10.3816/clm.2004.s.006. PMID: 15498147. 19: Cheson BD. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. BioDrugs. 2005;19(5):309-22. doi: 10.2165/00063030-200519050-00004. PMID: 16207072. 20: Smith BE. Ibritumomab tiuxetan: the cancer smart bomb. J Am Pharm Assoc (2003). 2003 May-Jun;43(3):437-8. doi: 10.1331/154434503321831175. PMID: 12836798.

View History

Nifurtoinol

Nifurtoinol